Michael Shapiro to Lipoprotein(a)
This is a "connection" page, showing publications Michael Shapiro has written about Lipoprotein(a).
Connection Strength
4.680
-
Marcovina SM, Shapiro MD. Measurement of Lipoprotein(a): A Once in a Lifetime Opportunity. J Am Coll Cardiol. 2022 Feb 22; 79(7):629-631.
Score: 0.794
-
Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K, Herrington DM, Shapiro MD. High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2021 Sep 14; 78(11):1083-1094.
Score: 0.770
-
Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23; 28(8):816-822.
Score: 0.698
-
Warden BA, Minnier J, Watts GF, Fazio S, Shapiro MD. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. J Clin Lipidol. 2019 Jul - Aug; 13(4):580-585.
Score: 0.653
-
Edmiston JB, Brooks N, Tavori H, Minnier J, Duell B, Purnell JQ, Kaufman T, Wojcik C, Voros S, Fazio S, Shapiro MD. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. J Clin Lipidol. 2017 May - Jun; 11(3):667-673.
Score: 0.563
-
Bhatia HS, Rikhi R, Allen TS, Yeang C, Guan W, Garg PK, Tsai MY, Criqui MH, Shapiro MD, Tsimikas S. Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2023 Sep; 381:117217.
Score: 0.220
-
Rikhi R, Hammoud A, Ashburn N, Snavely AC, Michos ED, Chevli P, Tsai MY, Herrington D, Shapiro MD. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2022 Dec; 363:102-108.
Score: 0.207
-
Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A, Blumenthal RS, Shapiro MD, Rodriguez CJ, Tsai MY, Sperling LS, Virani SS, Blaha MJ, Joshi PH. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022 Mar 01; 79(8):757-768.
Score: 0.199
-
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020 01 16; 382(3):244-255.
Score: 0.171
-
Mahmood T, Shapiro MD. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. Curr Opin Cardiol. 2019 09; 34(5):519-525.
Score: 0.167
-
Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB, Lambert G, Tsimikas S, Fazio S. PCSK9 Association With Lipoprotein(a). Circ Res. 2016 06 24; 119(1):29-35.
Score: 0.133
-
Krittanawong C, Maitra NS, El-Sherbini AH, Shah N, Lavie CJ, Shapiro MD, Virani SS. Lipoprotein(a) in clinical practice: A guide for the clinician. Prog Cardiovasc Dis. 2023; 79:28-36.
Score: 0.055
-
Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos RD, Shapiro MD, Saseen JJ. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis. 2022; 73:32-40.
Score: 0.049